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BRIEF ABSTRACT 
Heart-failure guidelines recommend up-titration of ACE-inhibitors/ARBs and beta-blockers to 
doses used in RCTs. These doses are often not reached, and might not benefit all patients. We 
determined the probability of mortality and/or heart-failure hospitalization based on a biomarker-
profile using 3 theoretical treatment scenarios: A) all patients are up-titrated to >50% 
recommended doses; B) patients are up-titrated according to a biomarker-based treatment-
selection model; C) no patient is up-titrated to >50% recommended doses.  
Up-titrating patients with heart-failure based on biomarker values might have resulted in fewer 
deaths and/or hospitalizations compared to a scenario in which all patients were successfully up-
titrated. 
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ABSTRACT 
Background 
Heart failure guidelines recommend up-titration of ACE-inhibitors/ARBs and beta-blockers to 
doses used in randomized clinical trials, but these recommended doses are often not reached. Up-
titration might however not be necessary in all patients. We aimed to establish the role of blood 
biomarkers to determine which patients should or should not be up-titrated.  
Methods 
Clinical outcomes of 2516 patients with worsening heart failure from BIOSTAT-CHF were 
compared between 3 theoretical treatment scenarios: A) all patients are up-titrated to >50% of 
recommended doses; B) patients are up-titrated according to a biomarker-based treatment-
selection model; C) no patient is up-titrated to >50% of recommended doses. We conducted 
multivariable Cox regression using 161 biomarkers and their interaction with treatment, 
weighted for treatment-indication bias to estimate the expected number of deaths and/or heart-
failure hospitalizations at 24 months for all three scenarios. 
Results 
Estimated death/hospitalization rates in 1802 patients with available (bio)markers were 16%, 
16%, and 26% respectively in ACE-inhibitor/ARB up-titration scenario A, B and C. Similar rates 
for beta-blocker up-titration scenarios A, B, and C were 23%, 19%, and 24%, respectively. If up-
titration was successful in all patients, an estimated 9.8, and 1.3 events per 100 treated patients 
could be prevented at 24 months by ACE-inhibitor/ARB or beta-blocker therapy. Similar 
numbers were 9.9 and 4.7 if up-titration treatment decision was based on a biomarker-based 
treatment-selection model.  
Conclusion 
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Up-titrating patients with heart failure based on biomarker values might have resulted in fewer 
deaths and/or hospitalizations compared to a hypothetical scenario in which all patients were 
successfully up-titrated. 
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INTRODUCTION 
 
Major improvements in pharmaceutical and device heart failure treatment of heart failure have 
been achieved in the past year. Evidence from large randomized clinical trials demonstrates that 
that angiotensin-converting-enzyme inhibitors (ACE-inhibitors) and beta-blockers improve 
clinical outcome in patients with mild to moderate heart failure (1–8). In large randomized 
clinical trials, treatment doses were up-titrated to pre-specified doses, which have become the 
guideline-recommended doses. (9–11). Despite these improvements and recommendations, the 
prognosis of patients with heart failure remains poor (12–15), and in daily clinical practice the 
majority of patients do not achieve recommended doses (16–18). Although it is expected that 
most patients that achieve recommended doses will benefit from treatment, selected patients 
might not benefit from the recommended doses, but will experience side effects of ACE-
inhibitors and beta-blocker treatment. A personalized medicine approach where patients who will 
not benefit from recommended ACE-inhibitor/ARB and beta-blocker heart failure treatment 
might be selected by biomarkers, and might reduce the number of patients receiving treatment 
without benefit and improve overall outcome. 
In this in silico study, we used data from the BIOSTAT-CHF project to identify such treatment-
selection markers. We hypothesized that biomarkers measured at baseline in serum/plasma of 
heart failure patients can identify whether patients benefit from recommended heart failure 
treatment or not. We developed models to estimate this benefit using 161 established and novel 
biomarkers, including standard biochemical blood-parameters. We compared three theoretical 
treatment scenarios: A) all patients are up-titrated to >50% of recommended doses according to 
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the ESC guidelines (9–11); B) patients will be up-titrated by a biomarker-based treatment-
selection model; C) no patient is treated at >50% of recommended dose. 
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METHODS 
 
Patients 
BIOSTAT-CHF is a multicenter prospective study of 2516 patients from 69 centers in 11 
European countries (19). Included patients were aged >18 years with symptoms of new-onset or 
worsening heart failure, confirmed either by a left ventricular ejection fraction (LVEF) of ≤40% 
or B-type Natriuretic Peptide (BNP) and/or (N-terminal pro) B-type natriuretic peptide (NT-
proBNP) plasma levels >400 pg/ml or >2,000pg/ml, respectively. At inclusion, patients were 
treated with either oral or intravenous furosemide ≥40 mg/day or equivalent at the time of 
inclusion, and were not previously treated with evidence based therapies (ACE-inhibitor/ARB 
and beta-blocker) or were receiving ≤ 50% of the target doses of these drugs at the time of 
inclusion and had an anticipated initiation or up-titration of ACE-inhibitor/ARB and/or beta-
blocker therapy by the treating physician. IRB approval was obtained in all countries. 
 
Evidence-based heart failure treatment 
Patients were treated according to evidence based ESC heart failure guidelines  available at time 
of inclusion (9–11). These recommend up-titrating patients to recommended doses of ACE-
inhibitors/ARBs and beta-blockers, unless not tolerated or contra-indicated (9–11). In 
BIOSTAT-CHF, sub-optimally treated patients were included, and physicians were encouraged 
to up-titrate patients to recommended treatment doses within 3 months after inclusion.  
We recently published data from BIOSTAT-CHF showing that up-titrating patients to 50-99% of 
recommended ACE-inhibitor/ARB and beta-blocker doses results in comparable survival and/or 
heart failure related hospitalization reduction compared with patients that reached 100% of 
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recommended doses (20). We therefore considered patients successfully up-titrated when >50% 
of recommended dose was achieved after 3 months of up-titration. All analyses were separately 
performed for ACE-inhibitors/ARBs and beta-blockers.  
 
Disease outcome 
Median follow-up of the BIOSTAT-CHF project was 21 months with an interquartile range of 
15-27 months. Primary patient outcome in BIOSTAT-CHF was the first occurrence of all-cause 
mortality or heart failure related hospitalization. Survival time was calculated from date of 
inclusion in BIOSTAT-CHF to date of death/heart failure hospitalization or date of censoring. 
Only patients who were at least followed for 3 months, were included in the present analysis. 
 
Biomarkers 
A total of 161 biomarkers were considered as treatment-selection markers. All markers were 
measured at inclusion of the patients. This included standard biochemical blood-parameters 
(hemoglobin, hematocrit, sodium, total cholesterol, HDL-cholesterol, LDL-cholesterol, glucose, 
serum creatinine, blood urea nitrogen (BUN), bilirubin, serum iron, potassium), heart failure 
markers (LVEF, NT-proBNP and BNP), 29 markers from the Luminex multiplexed bead-based 
immunoassay (Alere, San Diego, CA) heart failure panel (21, 22), and 92 peptide markers from a 
high-throughput technique using the Olink Proseek® Multiplex INF I96x96 kit, which measures 
92 selected inflammation-related proteins simultaneously in 1μl plasma samples. The kit uses a 
proximity extension assay (PEA) technology, where 92 oligonucleotide-labeled antibody probe 
pairs are allowed to bind to their respective target present in the sample 
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The 92 peptides measured by Olink® were normalized in arbitrary normalized protein 
expression units (NPX). Other biomarkers were normalized using Box-Cox transformations 
when deemed necessary. A complete list of all biomarkers and their summary statistics are 
shown in Supplemental Table S1. 
 
Statistical analysis 
1. Imputation of missing data 
Patients in whom >50% or more biomarker values were missing were not included in the 
analyses. Remaining missing values were imputed using random forests regression models 
implemented in the mice package (23) of the R statistical program (version 3.2.4) (24). Five 
completed data sets were created. 
 
2. Indication bias 
Since BIOSTAT-CHF is not a randomized study, we adjusted for treatment indication-bias. All 
analyses of the effect of successful up-titration treatment on mortality and/or hospitalization risk 
were inversely weighted with the probability of the given treatment. Given treatment is defined 
here as a successful up-titration to >50% of ESC recommended doses for ACE-inhibitor/ARB or 
beta-blocker or not. The probability of given treatment for a specific patient was modelled using 
a logistic regression model. All biomarkers were considered as predictor variables for successful 
up-titration. In addition, we considered 39 demographic and clinical predictor variables for 
prediction of the successful outcome of the up-titration (age, sex, race, BMI, blood pressure, 
heart rate, smoking, alcohol use, heart failure aetiology, heart failure duration, NYHA class, and 
several heart failure symptoms and comorbid conditions). We used lasso penalization to obtain 
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sparse logistic models consisting of a limited number of predictor variables. Optimal penalty 
parameters were obtained by 10-fold cross-validation. Analyses were performed for each 
imputed dataset and the calculated treatment probabilities were averaged per patient over the five 
imputed datasets. Performance of the logistic models was quantified using optimism-corrected c-
statistics using 100 bootstrap samples, averaged over the imputed datasets.  
 
3. Death and/or heart failure hospitalization and treatment-biomarker interaction 
Mortality and/or heart failure hospitalization risk was modelled using the Cox regression model 
with given treatment as a stratum-variable. Therefore, we did not assume proportional hazards 
for the effect of treatment on mortality/hospitalization risk. The assumed proportional hazards 
assumption of the biomarkers was checked using Grambsch and Therneau's test implemented in 
the cox.zph function of the R statistical program (25).  
We performed multivariable Cox regression with all 161 biomarkers. We used the split sample 
technique to obtain a training sample consisting of 80% of the patients in the original index 
cohort and the remaining 20% of the patients formed the test sample. The split-sample procedure 
was repeated 100 times. In all 100 training samples, we used lasso penalization to obtain sparse 
Cox regression models consisting of a limited number of the 161 biomarkers. Optimal penalty 
parameters were obtained by 10-fold cross-validation.  
We performed separate analyses for patients who were successfully up-titrated to >50% of 
recommended treatment dose for either ACE-inhibitors/ARB’s or beta-blockers and for patients 
who were not. This resulted in 4 different models predicting mortality and/or heart failure 
hospitalization; two models predicting mortality and/or heart failure hospitalization in 
successfully up-titrated patients for ACE-inhibitors/ARB’s and beta-blockers, and two for 
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patients up-titrated to less than 50% of recommended ACE-inhibitor/ARB and beta-blocker 
doses. We stratified on given treatment and considered both the main effects of all biomarkers as 
well as all interactions of biomarkers with treatment. In the 100 test samples, we subsequently 
evaluated the goodness of fit of the selected sparse Cox regression models. We calculated both 
calibration and discrimination statistics (c-statistic and shrinkage statistic). Moreover, the benefit 
of successful and not successful up-titration was calculated for the patients in the test samples. 
All analyses were inversely weighted with the probability of the given treatment to account for 
indication bias. 
 
4. Treatment benefit statistics 
We calculated the expected number of events at 24 months follow-up for three scenarios: A) if 
all patients are successfully up-titrated to >50% of recommended doses according to the ESC 
guidelines; B) if all patients are up-titrated following a treatment-strategy based on the biomarker 
values; C) if no patient is treated at >50% of recommended doses according to the ESC heart 
failure guidelines. We performed all analyses for ACE-inhibitor/ARB and beta-blocker 
separately. For scenario B; we decided to up-titrate when the probability of survival for mortality 
and/or hospitalization at 24 months for up-titrating were higher than for not up-titrating, and vice 
versa. 
The survival probabilities were based on the difference of a patient's mean death and/or heart 
failure hospitalization probability at 24 months follow-up (𝑆(𝑡 = 24| … )) under both treatments 
according to the sparse Cox regression models estimated for the associated training sample:  
𝑆(𝑡 = 24|𝑠𝑢𝑐𝑐𝑒𝑠𝑠𝑓𝑢𝑙 𝑢𝑝𝑡𝑖𝑡𝑟𝑎𝑡𝑖𝑜𝑛, 𝑋 = 𝑥) − 𝑆(𝑡 = 24|𝑢𝑛𝑠𝑢𝑐𝑐𝑒𝑠𝑠𝑓𝑢𝑙 𝑢𝑝𝑡𝑖𝑡𝑟𝑎𝑡𝑖𝑜𝑛, 𝑋 = 𝑥). 
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where 'X=x' represent specific levels of the biomarkers selected in the Cox models for predicting 
mortality and/or heart failure hospitalization in the successfully and not-successfully up-titrated 
patients, respectively. The difference was averaged over all test samples that included the 
specific patient, and was subsequently multiplied with total number of patients. This benefit-
statistic can be interpreted as the number of deaths and/or heart failure hospitalizations that is 
prevented at 24 months by successful up-titrating to >50% of recommended doses according to 
the ESC guidelines.  
Benefit-statistics were calculated for each test sample separately. The standard deviation of the 
benefit-statistics over the 100 test samples was then used as an estimate of the standard error of 
the mean benefit-statistic.  
 
RESULTS 
 
Of the 2516 patients included in the index cohort, 151 patients died, 23 patients were censored 
before 3 months follow-up and 242 patients had a LVEF >40%; these patients were excluded 
from the current data-analysis. Of the remaining 2100 patients, there were 298 patients with 
missing values on more than 50% of the biomarkers. Subsequent analyses were done with data 
from the remaining 1802 patients, corrected for indication-bias as presented in supplementary 
data. 
 
Multivariable treatment-selection markers  
To distinguish patients who benefited from up-titration from those who did not, we created two 
models. From 161 biomarkers, we first identified the strongest biomarkers to predict clinical 
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events (death of heart failure hospitalization) despite successful up-titration with either ACE-
inhibitors/ARBs or beta-blockers. Most frequently selected biomarkers are reported in 
Supplemental Table S2. BUN, FGF23 and pro-ENK were the strongest predictors of clinical events 
in patients that were successfully up-titrated with ACE-inhibitors/ARBs. Serum creatinine, 
galetin-3, ST2 and albumin were the strongest predictors of clinical events in patients that were 
successfully up-titrated with beta-blockers.  
In the second model, we identified the strongest biomarkers to predict clinical events in patients 
who were NOT successfully up-titrated with either ACE-inhibitors/ARBs or beta-blockers. 
FGF23, BUN, cystatin C, ST2, WAP-4C and IGFBP-2 were the strongest predictors of clinical 
events in patients that were NOT successfully up-titrated with ACE-inhibitors/ARBs. FGF23, 
cystatin C, BUN, WAP4C and NT-proBNP were the strongest predictors of clinical events in 
patients that were NOT successfully up-titrated with beta-blockers. The treatment-selection 
models had reasonable performances for the patients in the test sets. Averaged c-statistics for 
ACE-inhibitor/ARB models were 0.74 (0.68-0.80) in up-titrated patients, and 0.77 (0.70-0.83) in 
not-up-titrated patients, respectively. Beta-blocker treatment-selection models averaged c-
statistics were 0.75 (0.70-0.82) in up-titrated patients, and 0.78 (0.73-0.83) in not-up-titrated 
patients, respectively. 
Using both models, we were able to calculate survival probability at 24 months for both 
scenarios (successful or non-successful up-titration). The scenario with the highest probability 
was considered the most beneficial one for the individual patient. In 2% (42) of patients, the 
highest probability was found in patients who were not successfully up-titrated with ACE-
inhibitors/ARBs. Patients characteristics of these patients are presented in Table 3. Patients not 
benefitting from ACE-inhibitor/ARB up-titration were younger, more frequent smokers, with 
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less AF; higher haemoglobin and BUN, but lower heart rate and NT-proBNP levels. In 33% of 
patients, the highest survival probability was found in patients who were not successfully up-
titrated with beta-blockers. Patients characteristics of these patients are presented in Table 3. 
Patients not benefitting from beta-blocker up-titration were older, leaner, more frequently 
smoker or former smoker. The also had less ischemic HF, but more myocardial infarction, and 
other co-morbidities. They also had significantly higher LVEF, (NT-pro)BNP, BUN and 
creatinine, levels, and lower DBP, heart rate, haemoglobin and eGFR levels.  
 
Clinical events according to the three hypothetical scenarios 
Kaplan-Meier curves for ACE-inhibitor/ARB scenarios are presented in Figure 1. Mortality 
and/or heart failure hospitalization was highest in the scenario where no patient was up-titrated to 
at least 50% of the recommended dose. Patients who were up-titrated based on their biomarker 
profile had the lowest risk of death and/or heart failure hospitalization.  
Estimated event rate and averaged expected events at 24 months for each of the three 
hypothetical scenarios are presented in Table 2. If all patients were successfully up-titrated to 
>50% of recommended doses ACE-inhibitor/ARBs (Scenario A), estimated death and/or hospital 
admission occurred in 297 (260-335) patients. If patients were up-titrated with ACE-
inhibitor/ARBs following a treatment-strategy based on the biomarker values (Scenario B), 
estimated death and/or hospital admission occurred in 296 (260-333) patients. If no patient was 
treated with >50% of recommended doses ACE-inhibitor/ARBs (Scenario C), estimated death 
and/or hospital admission occurred in 474 (438-511) patients. Up-titrating ACE-inhibitor/ARBs 
to >50% of recommended dose compared to 50% less than recommended dose resulted in 174 
fewer events (95% CI 128-227) ; p-value= 0.0003). Per 100 treated patients, this means that 9.8 
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(95% CI 7.1-12.6) fewer events were seen in this scenario. The biomarkers-based approach led 
to 178 fewer events (95% CI 130-226 ; p-value=0.0003) compared to the 50% recommended 
dose group. Per 100 treated patients this resulted in 9.9 (95% CI 7.2-12.6) fewer events. 
Kaplan-Meier curves for beta-blocker scenarios are presented in Figure 2. Mortality and/or heart 
failure hospitalization was highest in the scenario where no patient was up-titrated to at least 
50% of the recommended dose. Patients who were up-titrated based on their biomarker profile 
had the lowest risk of death and/or heart failure hospitalization, which was slightly lower 
compared to a scenario in which all patients were up-titrated to >50% of the recommended dose 
of ACE-inhibitor/ARBs.  
Estimated event rate and averaged expected events at 24 months for each of the three 
hypothetical scenarios are presented in Table 2. If all patients were successfully up-titrated to 
recommended beta-blocker doses (Scenario A), estimated death and/or hospital admission 
occurred in 404 (95% CI 332-477) patients. If patients were up-titrated with beta-blockers 
following a treatment-strategy based on the biomarker values (Scenario B), estimated death 
and/or hospital admission occurred in 345 (95% CI 300-389) patients. If no patient was treated 
with recommended doses beta-blockers (Scenario C), estimated death and/or hospital admission 
occurred in 428 (95% CI 391-466) patients. Up-titrating beta-blockers to >50% of recommended 
dose compared to ≤50% resulted in 24 less events (95% CI -54-103); p-value=0.50). The 
biomarkers-based approach led to 84 fewer events (95% CI 40-128; p-value=0.01) compared to 
the ≤50% recommended dose group. This means that 1.3 (95% CI -3-5.7) and 4.7 (95% CI  2.2-
7.1) events could be prevented per 100 treated patients in both scenarios. 
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DISCUSSION 
We hypothesized that not every patient with HFrEF will benefit from maximal up-titration with 
either ACE-inhibitors/ARBs or beta-blockers. We therefore tested 3 hypothetical scenarios: A) 
all patients were up-titrated to >50% of recommended ACE-inhibitor/ARB or beta-blocker dose, 
B) all patients were up-titrated or not based on a biomarker model, and C) no patient was up-
titrated to >50% of recommended ACE-inhibitor/ARB or beta-blocker dose. Our models 
estimated that the highest number of events would have occurred in Scenario C) and the lowest 
number of events in Scenario B). The present results from this novel approach suggest that some 
patients do not benefit from maximally recommended doses. 
There are many biomarkers known to influence therapeutic response and survival (26, 27), and 
there have been many attempts to use biomarker levels for evaluating treatment response and 
outcome (28). However, no models were developed using a multitude of biomarkers to estimate 
and compare the risk of mortality and/or heart failure hospitalization in up-titrated and not up-
titrated patients. 
We recently published a meta-analysis on all prognostic heart failure models and an average c-
statistics for predicting mortality and/or heart failure related hospitalization of 0.68 (29). Thus, 
the biomarker-based treatment-selection models in the present paper have similar predictive 
performance compared to existing models. Most of these prognostic models were based on 
clinical and biographical patient-characteristics with few biomarkers. The association of some 
biomarkers that we identified (e.g. NT-proBNP, BUN, ST2, and hemoglobin) with mortality or 
heart failure hospitalization-risk in heart failure patients is well known (9, 10, 30–37), but a 
differential predictive value in patients who were successfully up-titrated versus those who were 
not, was as yet unknown. This observation may be useful to identify residual heart failure disease 
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and additional treatment targets in heart failure patients. Although our biomarker-based 
treatment-selection models have comparable performance to other prediction models, the 
performance of these models is still modest and they have large confidence bounds. In this study, 
we only looked at benefit, and did not take harm into account. Not up-titrating might be more 
beneficial for a patient, however up-titrating might not do harm. 
We decided to dichotomize up-titration into successful or not. In clinical practice, the actual 
doses of ACE inhibitors/ARB’s and beta-blockers vary substantially. Since we recently 
published data from BIOSTAT-CHF showing that up-titrating patients to 50-99% of 
recommended ACE-inhibitor/ARB and beta-blocker doses results in comparable survival and/or 
heart failure related hospitalization reduction (20), we considered patients successfully up-
titrated when >50% of recommended dose was achieved after 3 months of up-titration.  
The BIOSTAT-CHF population mainly consists of patients with advanced heart failure who may 
be more likely to have limited benefit from up-titration of ACE-inhibitor/ARB and beta-blocker 
therapy. These patients may be worsened by even small doses of beta-blockers, or they may 
experience excessive hypotension and worsening renal function from ACE-inhibitor/ARBs. 
BIOSTAT-CHF was specifically designed to record reasons for not uptitrating to recommended 
treatment doses. Only in 26 and 22% of the patients for ACE-inhibitors/ARBs and beta-blockers, 
this was caused by intolerance to the drug, either because of organ dysfunction. In the majority 
of patients, no specific reason was provided (20). This analysis supports the concept that even 
less clinical ill patients may not be helped by ACE-inhibitor/ARB and beta-blocker uptitration. 
There were significant hemodynamic differences (heart rate and blood pressure) between 
patients who were up-titrated >50% of recommended treatment dose and those who were not. 
This might suggest that these and other variables were at least partly responsible for the different 
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achieved up-titration doses. We corrected for these difference by propensity score matching and 
inverse probability of treatment weighing. 
 
Limitations 
One major important limitation of the present study is that heart failure treatment was not 
randomly assigned in our study. Up-titration of ACE inhibitor/ARB’s and beta-blockers has been 
shown to be beneficial on average in many randomized clinical trials and has been adopted into 
the ESC heart failure guidelines. It is striking, however, that in clinical practice so many patients 
are not up-titrated to >50% of recommended dose. We tried to adjust for this treatment-
indication bias, introduced in this cohort type BIOSTAT-CHF study, by two generally accepted 
advanced statistical methods: propensity scoring and inverse probability of treatment weighing. 
Whether this corrected the treatment-indication bias sufficiently is unfortunately not testable.  
A second limitation is the large number of biomarkers that we analysed which increased the 
chance of false positive findings. We used Bonferroni correction of p-values and we used sparse 
regression models to minimize the risk of overfitting. Lasso penalization is known to yield too 
large regression models (with too many predictor variables) (38), so our models might still be 
somewhat larger than necessary (on average > 23 biomarkers). We used a repeated split-sample 
technique to cross-validate benefit- and fit-statistics to reduce the effect of overfitting.  
A third limitation of our analyses is that we ignored patients who died in the first three months of 
up-titration period.  We excluded 151 deaths and the survival at three months was only 93%. We 
made a prediction model for the risk of death within 3 months and found that FGF23, NT-
proBNP, BNP, low haemoglobin, TNI, ET1, ST2, WAP4C and CRP were the most important 
predictors of death within 3 months. This selection of biomarkers coincided largely with the set 
of biomarkers that we identified as prognostic in the patients who were not successfully up-
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titrated for both ACE-inhibitors/ARBs and beta-blockers. Therefore, we assume that the 
presented results were not largely biased by the removal of the 151 deaths. 
Because not all biomarkers used in our treatment-selection models were measured in the 
validation cohort of BIOSTAT-CHF existing of 1728 patients, we unfortunately could not 
validate our results in this cohort. In the future, and when funding is available we aim to measure 
the missing biomarkers and validate our treatment-selection models in this cohort as well.  
We found substantial differences between patients of which the model assumed not to benefit 
from ACE-inhibitor/ARB up-titration and patients of which the model assumed not to benefit 
from beta-blocker up-titration. Patients not benefitting from ACE-inhibitor/ARB up-titration 
were younger, with lower BNP and NT-proBNP, higher haemoglobin levels. Patients not 
benefitting from beta-blocker up-titration, conversely, were more often older, had higher BNP 
and NT-proBNP, lower haemoglobin compared to patients benefitting from beta-blocker up-
titration. Blood urea nitrogen was elevated and heart rate was lower in both patients not 
benefitting from ACE-inhibitor/ARB up-titration and patients not benefitting from beta-blocker 
up-titration. 
A possible limitation that could not be addressed in our cohort is the fact that most of our patient 
were Caucasian. This would possibly limit the use of our biomarker-selection model in a more 
heterogeneous population. 
Biomarkers predictive for mortality and/or hospitalization, were also markedly different between 
patients who were successfully up-titrated or not. This might have been expected because 
biomarkers related to ACE inhibition/ARB and beta-blocking pathways are likely to change 
substantially as a result of up-titration (39).  
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Conclusion 
A biomarker-based treatment up-titration choice in patients with heart failure was favourable 
over both a hypothetical scenario in which all patients would have been successfully up-titrated 
to >50% of recommended of ACE-inhibitor/ARB and beta-blocker dose. We estimated that 1 in 
50 and 1/3 of patients will not benefit from ACE- inhibitor/ARB or beta-blocker up-titration, but 
their mortality/hospitalization hazards do not increase much by up-titration. And because of the 
nature of this study, and the small differences between biomarker-based treatment choice and the 
scenario in which all patients would have been successfully up-titrated, we suggest that up-
titration should always be attempted in heart failure patients, which should lead to improved 
treatment of life-saving therapies across Europe. 
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FIGURES AND TABLES  
Figure 1. Estimated Kaplan-Meier survival curves based on three scenarios. 
Estimated Kaplan-Meier survival curves with the expected event-free survival rate and time in months based on 
three scenarios (green, blue and red lines): A) if all patients were up-titrated to >50% of recommended ACE-
inhibitor/ARB dose (green); B) if all patients were up-titrated according to biomarker-selection model (blue); C) if 
no patient was up-titrated to >50% of recommended ACE-inhibitor/ARB dose (red), with 95% confidence interval.  
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Figure 2. Estimated Kaplan-Meier survival curves based three scenarios 
Estimated Kaplan-Meier survival curves with the expected event-free survival rate and time in months based on 
three scenarios (green, blue and red lines): A) if all patients were up-titrated to >50% of recommended beta-blocker 
dose (green); B) if all patients were up-titrated according to biomarker-selection model (blue); C) if no patient was 
up-titrated to >50% of recommended of beta-blocker dose (red), with 95% confidence interval.  
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Table 1: Baseline characteristics of the patients who were up-titrated to >50% of recommended 
ACE-inhibitor/ARB and beta-blocker dose and those who were not. 
 
ACE-inhibitor/ARB 
 
beta-blocker 
 
  
successful  
up-titration 
no successful  
up-titration P - value 
successful  
up-titration 
no successful  
up-titration P - value 
Number of patients: n (%) 529 1273   318 1484   
% of recommended ACE-inhibotor/ARB dose: mean (SD) 100 (28) 29 (18)   61 (39) 48 (38)   
% of recommended beta-blocker dose: mean (SD) 45 (32) 34 (30)   93 (18) 25 (17)   
Age (years): mean (SD) 66.36 (11.85) 68.15 (12.12) 0.004 66.14 (12.63) 67.94 (11.92) 0.02 
Male gender: n (%) 395 (75%) 967 (76%) 0.56 235 (74%) 1127 (76%) 0.44 
Caucasian ethnicity: n (%) 523 (99%) 1259 (99%) 0.29 314 (99%) 1468 (99%) 0.04 
BMI (kg/m2): mean (SD) 28.93 (6.02) 27.49 (5.26) <0.00001 28.41 (5.57) 27.81 (5.51) 0.09 
Systolic blood pressure: mean (SD) 130.04 (22.37) 121.24 (20.5) <0.00001 125.47 (21.7) 123.46 (21.37) 0.13 
Diastolic blood pressure (mmHg): mean (SD) 79.03 (13.71) 73.68 (12.6) <0.00001 78.35 (14.45) 74.58 (12.77) 0.00002 
Heart rate (bpm): mean (SD) 79.88 (20.33) 79.97 (19.19) 0.93 85.3 (22.25) 78.8 (18.7) <0.00001 
Smoking (current/ever/never): n 197/256/76 450/630/193 0.73 101/177/40 546/709/229 0.04 
Alcohol use: n (%) 368 (70%) 909 (71%) 0.45 203 (64%) 1074 (72%) 0.003 
Ischemic HF etiology: n (%) 261 (49%) 563 (44%) 0.05 163 (51%) 661 (45%) 0.03 
HF duration (years): median (IQR) 8.81 (4.43-14.09) 7.59 (3.34-13.2) 0.5 8.54 (3.77-17.02) 7.64 (3.49-12.72) 0.39 
NYHA class III/IV: n (%) 244 (46%) 509 (40%) 0.02 134 (42%) 619 (42%) 0.89 
LVEF: median (IQR) 29 (24-34) 28 (22-34) 0.0005 29 (24-34) 29 (24-34) 0.3 
NT-proBNP, ng/L: median (IQR) 32109 (29824-34465) 33454 (30868-35940) 0.00001 32593 (30378-35101) 32919 (30630-35676) 0.19 
Oedema, % (n) 228 (43%) 603 (47%) 0.1 156 (49%) 675 (45%) 0.25 
Orthopnoea, % (n) 150 (28%) 431 (34%) 0.02 82 (26%) 499 (34%) 0.006 
Rales >1/3 up lung fields, % (n) 44 (19%) 125 (19%) 0.98 17 (12%) 152 (20%) 0.03 
Jugular venous pressure, % (n) 111 (29%) 281 (31%) 0.45 63 (28%) 329 (31%) 0.37 
Hepatomegaly, % (n) 60 (11%) 184 (14%) 0.07 39 (12%) 205 (14%) 0.45 
Hypertension, % (n) 349 (66%) 731 (57%) 0.0007 195 (61%) 885 (60%) 0.58 
Atrial fibrillation, % (n) 209 (40%) 564 (44%) 0.06 163 (51%) 610 (41%) 0.0009 
Myocardial infarction, % (n) 188 (36%) 491 (39%) 0.23 113 (36%) 566 (38%) 0.38 
PCI, % (n) 106 (20%) 285 (22%) 0.27 72 (23%) 319 (21%) 0.65 
CABG, % (n) 70 (13%) 220 (17%) 0.03 47 (15%) 243 (16%) 0.48 
Device therapy   0.02   0.52 
None 427 (80%) 932 (73%) 
 
234 (74%) 1125 (76%) 
 Pacemaker only 28 (5%) 89 (7%)   16 (5%) 101 (7%)   
ICD only 31 (6%) 121 (10%)   30 (9%) 122 (8%)   
CRT only 11 (3%) 24 (2%)   7 (2%) 28 (2%)   
ICD and CRT 31 (6%) 102 (8%)   30 (6%) 103 (7%)   
Other 1 (0%) 5 (0%)   1 (0%) 5 (0%)   
Diabetes mellitus, % (n) 182 (34%) 389 (31%) 0.11 97 (31%) 474 (32%) 0.62 
COPD, % (n) 70 (13%) 220 (17%) 0.03 42 (13%) 248 (17%) 0.12 
Stroke, % (n) 40 (8%) 122 (10%) 0.17 20 (6%) 142 (10%) 0.06 
Peripheral artery disease, % (n) 46 (9%) 142 (11%) 0.12 27 (8%) 161 (11%) 0.21 
Aldosterone antagonists, % (n) 267 (50%) 719 (56%) 0.02 150 (47%) 836 (56%) 0.003 
Loop diuretics, % (n) 526 (99%) 1268 (100%) 0.61 317 (100%) 1477 (100%) 0.7 
Digoxin, % (n) 82 (16%) 242 (19%) 0.08 54 (17%) 270 (18%) 0.61 
Haemoglobin, g/dL: mean (SD) 12.69 (1.73) 12 (2) <0.00001 12.52 (1.81) 12 (2) 0.13 
Creatinine, Œºmol/L: median (IQR) 481 (470-500) 491 (470-515) <0.00001 484 (467-506) 487 (467-510) 0.19 
BUN, mmol/L: median (IQR) 25.5 (24.2-31.6) 29 (24-35) <0.00001 26.7 (23.5-32.4) 28 (23-34) 0.005 
GFR MDRD formula, mL/min.1.73m2: mean (SD) 71 (22) 64 (24) <0.00001 68 (24) 65 (23) 0.09 
Sodium, mmol/L: mean (SD) 138.85 (3.55) 138.06 (3.81) 0.00004 138.62 (3.46) 138.22 (3.81) 0.07 
Potassium, mmol/L: mean (SD) 3.24 (0.53) 3.29 (0.56) 0.07 3.24 (0.51) 3.28 (0.56) 0.2 
 31 
BNP, pg/mL: median (IQR) 3931 (3624-4227) 4010 (3624-4438) 0.04 3966 (3496-4482) 3984 (3496-4343) 0.92 
 BNP: brain natriuretic peptide; BUN: blood urea nitrogen; CRT: cardiac resynchronization therapy ; GFR: glomerular filtration rate; ICD: 
implantable cardioverter-defibrillator IQR: interquartile range; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; N-
terminal prohormone of BNP; SD: standard deviation 
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Table 2: Estimation of mortality and/or heart failure hospitalizations at 24 months three 
scenarios: Scenario A) if all patients are successfully up-titrated to more than 50% of 
recommended dose; scenario B) if up-titration was based on the biomarker treatment-selection 
model; scenario C) if no patient was successfully up-titrated for ACE-inhibitors/ARB’s.  
 
ACE-inhibitor/ARB Scenario A Scenario B  Scenario C 
Estimated event rate at 24 months  16% 16% 26% 
Estimated number of events (95% CI) 297 (260-335) 296 (260-333) 474 (438-511) 
Estimated event reduction compared to scenario C (95% CI) 177 (128-227) 178 (130-226) - 
Estimated event reduction compared to scenario C (95% CI) per 
100 treated patients 
9.8 (7.1-12.6) 9.9 (7.2-12.6)  
 
Beta-blocker Scenario A Scenario B  Scenario C 
Estimated event rate at 24 months 23% 19% 24% 
Estimated number of events (95% CI) 404 (332-477) 345 (300-389) 428 (391-466) 
Estimated event reduction compared to scenario C (95% CI) 24 (-54-102.55) 84 (40-128) - 
Estimated event reduction compared to scenario C (95% CI) per 
100 treated patients 
1.3 (-3-5.7) 4.7 (2.2-7.1)  
Scenario A) if all patients are successfully up-titrated; scenario B) if up-titration was based on the biomarker treatment-selection model; scenario 
C) if no patient was successfully up-titrated; CI: confidence interval 
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Table 3: Characteristics of patients who did benefit from ACE-inhibitor/ARB or beta-blocker 
up-titration and those who did not. 
  ACE-inhibitor/ARB beta-blocker 
 
  benefit uptitration 
NOT benefit 
uptitration 
P-
value benefit uptitration 
NOT benefit 
uptitration P-value 
Number of patients: n (%) 1760 (98) 42 (2%)   1210 (67) 592 (33)   
% of recommended ACE-inhibotor/ARB dose: mean 
(SD) 50 (39) 57 (41)   51 (38) 47 (40)   
% of recommended beta-blocker dose: mean (SD) 37 (31) 41 (32)   37 (31) 36 (32)   
Age (years): mean (SD) 67.72 (12) 63.37 (14) 0.05 65.93 (12.13) 71.08 (11.18) <0.00001 
Male gender: n (%) 1331 (76%) 31 (74%) 0.79 922 (76%) 440 (74%) 0.38 
Caucasian ethnicity: n (%) 1742 (99%) 40 (95%) 0.08 1194 (99%) 588 (99%) 0.54 
BMI (kg/m2): mean (SD) 27.89 (5.55) 28.82 (4.22) 0.18 28.37 (5.72) 26.99 (4.98) <0.00001 
Systolic blood pressure: mean (SD) 123.67 (21.46) 129.81 (19.94) 0.06 124.26 (21.77) 122.9 (20.73) 0.2 
Diastolic blood pressure (mmHg): mean (SD) 75.18 (13.15) 78.07 (13.62) 0.18 76.23 (13.53) 73.23 (12.13) <0.00001 
Heart rate (bpm): mean (SD) 80.05 (19.63) 75.24 (13.49) 0.03 80.91 (19.36) 77.97 (19.72) 0.003 
Smoking (current/ever/never): n 626/866/268 21/20/1 0.03 417/584/209 230/302/60 0.0003 
Alcohol use: n (%) 1246 (71%) 31 (74%) 0.68 857 (71%) 420 (71%) 0.94 
Ischemic HF etiology: n (%) 801 (46%) 23 (55%) 0.23 582 (48%) 242 (41%) 0.004 
HF duration (years): median (IQR) 8.02 (3.55-13.4) 3.54 (1.6-6.59) 0.2 8.34 (3.78-13.54) 6.38 (2.61-12.46) 0.31 
NYHA class III/IV: n (%) 731 (42%) 22 (52%) 0.16 498 (41%) 255 (43%) 0.44 
LVEF: median (IQR) 29 (24-34) 29 (24-34) 0.19 27 (23-34) 29 (24-34) 0.00001 
NT-proBNP, ng/L: median (IQR) 
32900 (30630-
35620) 27928 (26980-32965) 0.01 
32635 (30247-
35086) 33593 (31140-36655) 0.00003 
Oedema, % (n) 818 (46%) 13 (31%) 0.05 558 (46%) 273 (46%) 1 
Orthopnoea, % (n) 567 (32%) 14 (33%) 0.88 404 (33%) 177 (30%) 0.14 
Rales >1/3 up lung fields, % (n) 166 (19%) 3 (14%) 0.58 108 (18%) 61 (20%) 0.43 
Jugular venous pressure, % (n) 387 (31%) 5 (16%) 0.07 256 (30%) 136 (31%) 0.8 
Hepatomegaly, % (n) 240 (14%) 4 (10%) 0.44 166 (14%) 78 (13%) 0.75 
Hypertension, % (n) 1052 (60%) 28 (67%) 0.37 713 (59%) 367 (62%) 0.21 
Atrial fibrillation, % (n) 763 (43%) 10 (24%) 0.01 517 (43%) 256 (43%) 0.84 
Myocardial infarction, % (n) 668 (38%) 11 (26%) 0.12 415 (34%) 264 (45%) 0.00002 
PCI, % (n) 385 (22%) 6 (14%) 0.24 248 (20%) 143 (24%) 0.08 
CABG, % (n) 282 (16%) 8 (19%) 0.6 180 (15%) 110 (19%) 0.04 
Device therapy   0.31   0.39 
None 1326 (74%) 33 (79%) 
 
927 (51%) 432 (73%) 
 Pacemaker only 116 (6%) 1 (2%)   70 (7%) 47 (8%)   
ICD only 151 (8%) 1 (2%)   101 (8%) 51 (8%)   
CRT only 34 (2%) 1 (2%)   25 (2%) 10 (2%)   
ICD and CRT 127 (7%) 6 (2%)   83 (5%) 50 (8%)   
Other 6 (0%) 0 (0%)   4 (0%) 2 (0%)   
Diabetes mellitus, % (n) 560 (32%) 11 (26%) 0.44 367 (30%) 204 (34%) 0.08 
COPD, % (n) 287 (16%) 3 (7%) 0.11 194 (16%) 96 (16%) 0.92 
Stroke, % (n) 162 (9%) 0 (0%) 0.04 101 (8%) 61 (10%) 0.17 
Peripheral artery disease, % (n) 185 (11%) 3 (7%) 0.48 120 (10%) 68 (11%) 0.31 
Aldosterone antagonists, % (n) 966 (55%) 20 (48%) 0.35 692 (57%) 294 (50%) 0.003 
Loop diuretics, % (n) 1752 (100%) 42 (100%) 0.66 1203 (99%) 591 (100%) 0.22 
Digoxin, % (n) 321 (18%) 3 (7%) 0.06 231 (19%) 93 (16%) 0.08 
Haemoglobin, g/dL: mean (SD) 12.36 (1.85) 13 (1) 0.004 12.79 (1.73) 11.53 (1.78) <0.00001 
Creatinine, Œºmol/L: median (IQR) 486 (461-510) 488 (461-508) 0.55 482 (476-502) 500 (476-527) <0.00001 
BUN, mmol/L: median (IQR) 28 (26.9-33.6) 33 (27-36) 0.002 27.4 (24.4-32.8) 29.2 (24.4-35.3) 0.0001 
GFR MDRD formula, mL/min.1.73m2: mean (SD) 66 (23) 70 (25) 0.29 70 (22) 56 (23) <0.00001 
Sodium, mmol/L: mean (SD) 138.28 (3.75) 138.95 (3.88) 0.27 138.42 (3.64) 138.03 (3.97) 0.04 
Potassium, mmol/L: mean (SD) 3.27 (0.55) 3.29 (0.53) 0.86 3.26 (0.53) 3.31 (0.58) 0.08 
BNP, pg/mL: median (IQR) 3985 (2090-4357) 3124 (2090-3823) 0.04 3914 (3744-4282) 4182 (3744-4457) 0.008 
 
